Myriad Genetics Reports Preliminary Q4 Revenue; Issues 2026 Guidance

Myriad Genetics is forecasting Q4 total revenues of $207m–$209m and full-year 2025 revenues of $822m–$824m, and will report actual Q4 results on its February 2026 earnings call. For fiscal 2026 the company projects revenue of $860m–$880m and adjusted EBITDA of $37m–$49m, signaling modest top-line growth and a return to positive adjusted EBITDA that should inform investor expectations ahead of the release.

Analysis

Market structure: Myriad (MYGN) is the clear direct beneficiary of a modestly constructive guide—FY25 revs $822–824M and FY26 revs $860–880M imply ~4–7% top‑line growth and implied adjusted EBITDA margin of roughly 4.3–5.6% (37–49M / revenue). Competitors with less diversified revenue or higher opex (NTRA, NVTA) face relative downside if MYGN solidifies payer coverage; payers could gain negotiating leverage if pricing is stable. Supply/demand appears steady for hereditary and oncology testing rather than expanding rapidly, so pricing power is limited; impact on bond markets is incremental—improving EBITDA could modestly tighten MYGN credit spreads, while options IV should compress into and after the Feb 2026 call.

Risk assessment: Key tail risks are a CMS reimbursement change (>10% cut) or adverse coverage decisions that could reduce revenue by >10% and pressure cash flow, plus sudden patent/regulatory actions or major lab operational failures. Time horizons: immediate (days) around the Feb call and guidance reaction, short-term (weeks/months) for payer/coverage shifts, long-term (quarters/years) for durable adoption and margin expansion. Hidden dependencies include concentration by test type and payer mix, reagent/lab capacity constraints, and potential one-off revenue recognition; catalysts include the Feb 2026 earnings call, any CMS notices in 30–60 days, and competitor pricing moves.

Trade implications: For directional exposure favor equity or limited‑risk option structures sized 1–3% of portfolio—shares if you want capture dividends of upside, or 9–12 month call spreads to limit premium risk. Consider a relative value pair (long MYGN vs short NTRA/NVTA) to express confidence in margin leverage vs growth burn names. Enter ahead of the Feb call to capture directional bias, but trim into the 48–72 hour post‑earnings volatility window; if FY26 revs fall below $860M or EBITDA < $37M, de-risk immediately.

Contrarian angles: Consensus may underweight the chance of margin expansion if MYGN converts higher‑value tests or tightens payer contracts—beat + EBITDA >$45M could prompt a re‑rating. Conversely, the market could be underreacting to downside reimbursement risk; historical parallels include diagnostics re‑ratings after payer clarity (LabCorp/Quest episodes) where clarity swung multiples by 3–5x PE points. Unintended consequences of an upside (higher margins) include renewed competitive entry and regulatory scrutiny that can compress forward multiples rapidly.

Key Decisions for Investors

• Establish a 2–3% long position in MYGN common stock ahead of the Feb 2026 earnings call; target 25–40% upside over 6–12 months if FY26 revenue ≥ $860M and adjusted EBITDA > $40M, with a hard stop‑loss at 15% adverse move.
• Buy a limited‑risk MYGN 12‑month call spread (buy 1 LEAP call ~30% OTM, sell 1 LEAP call ~60% OTM) sized to 1–2% portfolio notional to cap premium; close if premium decays >50% or if stock gaps down >25% on earnings.
• Implement a pair trade: Long MYGN (2% portfolio) / Short NTRA (1.5%) to capture relative margin leverage; unwind if the relative spread compresses by 30% or after 3 months without divergence.
• Reduce exposure to high‑burn genomics growth names (e.g., NVTA) by ~30% within 30 days and reallocate proceeds to diagnostics names with cash generation (MYGN, LH) to favor free‑cash‑flow positive balance sheets.
• If CMS or a major payer issues a proposed molecular diagnostics reimbursement cut >10% within the next 60 days, reduce MYGN exposure to <0.5% or exit entirely given >10% downside revenue sensitivity.